Vyrų krūties vėžio diagnostika ir gydymas

Algirdas Jackevičius, Leonarda Šarakauskienė, Valerijus Ostapenko, Saulius Bružas, Juozas Kurtinaitis, Algimantas MudėnasVilniaus universiteto Onkologijos institutas,Santariškių g.1, LT-08660 VilniusKauno medicinos universiteto Onkologijos ligoninė,Volungių g. 16, LT-45434 KaunasEl paštas: [email protected] Įvadas / tikslas Vyrų krūties vėžys yra reta onkologinė liga. Šiame straipsnyje pateikiame 75 ligonių, gydytų dviejose onkologijos ligoninėse, klinikinius duomenis, tiesioginius ir vėlyvuosius gydymo rezultatus. Ligoniai ir metodai Straipsnyje nagrinėjami Vilniaus universiteto Onkologijos instituto klinikoje ir Kauno universiteto Onkologijos ligoninėje1988–2003 metais gydytų 75 vyrų, sirgusių krūties vėžiu, klinikiniai duomenys. Ligonių amžiaus vidurkis – 69,2 metų (jauniausias 41, vyriausias 90 metų). Aštuoniems (10,7%) ligoniams diagnozuotas pirmos stadijos vėžys, 35 (46,7%) – antros, 22 (29,3%) – trečios, 10 (13,3%) ligonių – ketvirtos. Pagal histologinius vėžio tipus dažniausiai diagnozuota intraduktalinė karcinoma – 40 ligonių, 8 ligoniams – lobulinė karcinoma, tačiau 14 ligonių vėžio histologinis tipas nenustatytas. Dažniausiai, t. y. 53 ligoniams, buvo atlikta modifikuota Maddeno mastektomija, aštuoniems – paprastoji mastektomija, 8 ligoniams taikyta spindulinė terapija, 6 ligoniams dėl sunkių gretutinių ligų – simptominis gydymas. 37 ligoniai gydyti kombinuotu būdų: 30 – spinduline terapija, 5 – chemoterapija, 2 – abiem gydymo metodais. Rezultatai Vėlyvieji gydymo rezultatai nebuvo geri: iš 75 gyvena 28 liginiai, 47 mirė. Penkerius metus išgyveno 83,3% (95% PI 27,3–97,5) sergančiųjų pirmos stadijos krūties vėžiu, 69,6% (95% PI 49,1–83,1) – antros stadijos ir tik 6,2% (95% PI 4,2–24,2) – trečios. Nė vienas ligonis, kuriam diagnozuota ketvirta ligos stadija, neišgyveno penkerių metų. Išvados Lietuvoje vyrų sergamumas krūties vėžiu per pastaruosius metus nepakito. Nemažai vyrų buvo gydyti nuo IIIB stadijos krūties vėžio, kai navikas jau buvo lokaliai išplitęs ir susiformavo vėžinė opa. Vyrų, sergančių trečios stadijos krūties vėžiu, prognozė yra blogesnė negu moterų. Ligos stadija nulemia ligonių gyvenimo trukmę, tai patvirtina statistinis vėlyvųjų gydymo rezultatų skaičiavimas. Reikšminiai žodžiai: vyrų krūties vėžys, diagnostika, gydymas, vėlyvieji rezultatai The diagnostics and treatment of male breast carcinoma Algirdas Jackevičius, Leonarda Šarakauskienė, Valerijus Ostapenko, Saulius Bružas, Juozas Kurtinaitis, Algimantas MudėnasVilnius University Institute of Oncology,Santariškių str. 1, LT-08660 Vilnius, LithuaniaKaunas Medical University Oncological Hospital,Volungių str. 16, LT-45434, Kaunas, LithuaniaE-mail: [email protected] Background / objective Male breast cancer is an uncommon oncological disease. In this paper, we have analysed the results of treatment of 75 patients treated in two oncologycal clinics. Patients and methods We analysed 75 male patients treated in 1988–2003 in the clinics of the Institute of Oncology of Vilnius University and Hospital of Oncology of Kaunas University of Medicine. The mean age of patients was 69.2 years (range, 46–90 years). The staging of disease: stage I 8 (10.7%) patients, stage II 35 (46.7%), stage III 22 (29.3%). Ten (13.3%) patients were treated in stage IV of the disease. The most common method of treatment was radical mastectomy by Madden which was performed in 53 cases. In 8 cases mastectomy simplex was performed. Eight patients received radiotherapy. The patients received this conservative treatment in late stages of the disease. In seven cases the patients were in poor health state, and only palliative treatment was applied. 37 patients received combined treatment: 30 patients were treated with radiotherapy, two patients received radiotherapy and chemotherapy, in 5 cases after mastectomy the patients were treated with chemotherapy. Results The follow-up results were not satisfactory: from 75 patients 28 patients are alive and 47 died. The 5-year survival of the patients according to the stage of disease: 83.3% (95% CI 27.3–97.5) of patients in stage I, 69.6% (95% CI 49.1–83.1) in stage II, stage III 6.2% (95% CI 4.2–24.2). In this period, all patients in stage IV of the disease died. Conclusions The incidence of male breast cancer in Lithuania is low, and over the last years has remained at the same level. Many of our patients had ulceration of tumor and were treated in stage III B of the disease. The prognosis of male breast cancer in stage III of the disease is worse than of female breast cancer of the same stage. The stage of the disease was statistically significant for the survival of patients. Keywords: male breast carcinoma, diagnosis, treatment, follow-up results

Download Full-text

Tumor-Infiltrating Lymphocytes in Breast Carcinoma: Immunohistochemical Analysis

International Journal of Innovative Research in Medical Science ◽

10.23958/ijirms/vol03-i12/501 ◽

2018 ◽

Vol 3 (12) ◽

Author(s):

Dr. Amol R. R. Rajhans, MD ◽

Dr. Deepak S. Howale

Keyword(s):

Breast Cancer ◽

Breast Carcinoma ◽

T Lymphocytes ◽

Clinical Stage ◽

Stage Iv ◽

Stage I ◽

Stage Ii ◽

Stage Iii ◽

Cd4 Cells ◽

Infiltrating Lymphocytes

Breast cancer is the most common invasive cancer in women, and the second main cause of cancer death in women, after lung cancer. Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. In those with distant spread of the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin. In 2017, around 252, 710 new diagnoses of breast cancer are expected in women, and around 40,610 women are likely to die from the disease. Awareness of the symptoms and the need for screening are important ways of reducing the risk. Material and Methods: This retrospective study was carried out in the department of Pathology, DCP Consultant Pathologist Shashwat Hospitals, Pune, a total of 38 retrospective breast carcinoma tissues were obtained from female patients. Representative paraffin blocks and haematoxylin and eosin (HandE)-stained sections were retrieved from the pathology department. The patients' records were reviewed to look for the patient age and the clinical stage of the disease. The stage of the cancer was reported according to the American Joint Committee of Cancer. As tissue and patient data was collected in an anonymous way no written or informed consent was required for the study purpose. Results and Observations: According to data by clinical staging Stage I, Stage II, Stage III and Stage IV were 16 (42.11%), 11(28.95%), 7 (18.42%) and 4 (10.53%) respectively. According to histology Stage I, Stage II, Stage III and Stage IV were 2 (5.26%), 11(28.95%), 24 (63.16%) and 1 (2.63%) respectively. Hand E-stained sections showed that tumour-infiltrating lymphocytes (TILs) were present in 31 of the 38 carcinomas (81.58%). Majority of theTILs were T lymphocytes and was present in all 31 cases. CD4+ cells were seen31 patients and CD 8+ were seen in 25 cases. B cells were seen in 21 cases. TILs were analysed according to the clinical stage of breast cancer, stages III and IV tumors showed significantly higher densities of total lymphocytes, T lymphocytes, and CD4+ lymphocytes as compared to stage II tumors. Lymphocyte immuno phenotypes and the total TILs also showed a high significantly positive correlation between each lymphocyte population/subpopulation and the total TILs. Conclusion: T and B lymphocytes were expressed in breast carcinoma with High prevalence of T lymphocytes CD4+ cells. However larger no of cases are required to confirm the findings and extensive large studies are required.

Download Full-text

Early-stage male breast cancer: A 10-year experience

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.e11630 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. e11630-e11630

Author(s):

N. Gercovich ◽

E. Gil Deza ◽

M. Russo ◽

C. Garcia Gerardi ◽

C. Diaz ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Male Breast Cancer ◽

Ductal Carcinoma ◽

Early Stage ◽

Male Breast ◽

Stage I ◽

Stage Ii ◽

Breast Cancers ◽

Breast Cancer Patients

e11630 Introduction: Male breast cancer is very rare, representing only between 0.7% and 1% of all breast cancers, and only half of them are early stage cases. Objective: The present study has been designed with the aim of studying retrospectively the clinical onset and evolution of male invasive breast cancer patients (stages I and II) treated at IOHM between 1997 and 2008. Methods: The records of 3,000 breast cancer cases followed between 1997 and 2008 were searched, looking for male stage I and II breast cancer patients. A database was designed following the recommendations of the Directors of Surgical Pathology of the USA. The information registered encompassed: adjuvant treatments, recurrence date and date of final consultation or death. Results: Twelve pts were identified. Mean age (range)= 66 yo (50–89 yo). Tumoral type= Invasive Ductal Carcinoma 12 pt. Tumoral subtype= NOS 9 pt (75%) Apocrine 2 pt (17%) Micropapillar 1 pt (8%). Nottingham´s grade= Grade 2: 8 pt, Grade 3: 3 pt, N/A=1 pt. Stage= I= 6 pt, II=6 pt. ER (Positve= 9 pt, Negative=1 pt, N/A= 2 pt). PR (Positve= 8 pt, Negative= 2 pt, N/A=2 pt). Her2neu (0+= 3 pt, 1+= 3 pt, 2+= 2 pt, N/A= 4 pt). Surgery= Mastectomy= 11 pt, Lumpectomy 1= pt. Radiotherapy=5 pt. Adjuvance= No=2 pt, Hormonotherapy (HT)= 3 pt, Chemotherapy (CHT) = 3 pt, CHT+HT= 4 pt. Recurrence= Yes= 2 pt, No= 10 pt. Survival: Dead= 1 pt, Alive =11 pt. Mean Time To Progression= Stage I =66 months, Stage II =42 months. Global survival: Stage I =66 months, Stage II =52 months. Conclusions: 1. Twelve stage I and II male breast cancer patients were identified out of 3000 (0.4%) breast cancer cases diagnosed and followed in the past 10 years at the IOHM. 2. Mastectomy was the surgical procedure in 11 of the 12 cases 3. Ten pt underwent adjuvant treatment. 4. With a mean follow up time of 60 months, all stage I patients are alive and there were no recurrences. Two of the 6 stage II pts progressed and one died. No significant financial relationships to disclose.

Download Full-text

Triple-negative breast cancer: Epidemiology, characteristics, and survival in a Lebanese cohort

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.e22228 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. e22228-e22228

Author(s):

M. Ghosn ◽

C. Hajj ◽

F. Nasr ◽

F. El Karak ◽

G. Abadjian ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Ductal Carcinoma ◽

Positive Family History ◽

Disease Free Survival ◽

Stage Iv ◽

Stage I ◽

Stage Ii ◽

University Hospital ◽

Stage Iii

e22228 Background: Breast cancer (BC) is the most common malignancy in women in Lebanon. Triple negative (TN) phenotype is known to be associated with an increased likelihood of recurrence and death. The purpose of this study is to determine the incidence, characteristics and survival of TN BC patients in a Medical Oncology department in a University Hospital in Lebanon. Methods: We retrospectively reviewed the pathology of all women with breast cancer that were seen in our institution between 1997 and 2008. TN BC patients (pts) were defined as those that were negative for all 3 receptors (estrogen, progesterone and HER2neu on immunohistochemistry). Pts' characteristics and survival of TN women were analyzed. Results: Of the 1599 breast cancer pts, 155 (9.7%) had a triple negative phenotype. Median age was 52 years. A positive family history of breast/ovarian cancer was found in 15 pts (10%). Pathology studies showed: invasive ductal carcinoma component in 138 pts (89%), pure medullary carcinoma in 7 pts (5%), pure invasive lobular carcinoma in 6 pts (4%), pure mucinous carcinoma in 3 pts (2%) and epidermoid carcinoma in 1 pt (1%). A grade III was found in 98 of specimens (63%). Twenty-six pts (17%) presented with stage I, 73 (47%) with stage II, 37 (24%) with stage III and 19 (12%) with stage IV. Twelve percent had inflammatory breast cancer. After a median follow up of 17 months (mths), 43 pts had relapsed (5 stage I, 18 stage II and 20 stage III). The most common sites of relapse were brain (in 20 % of cases), lungs (in 20% of cases) and bone (in 11% of cases). Five- year disease free survival and 5-year overall survival were respectively 75% and 88% for stage I, 58% and 72% for stage II and 40% and 63% for stage III. Adjuvant therapy was administered to 96% of pts among which a taxane-based regimen was used in 38% of cases . Median survival for stage IV was 19 mths with a first line taxane-based regimen used in 50% of cases. Conclusions: The incidence of TN BC in Lebanon is similar to that described in the literature. It has an aggressive course. Focus on understanding the biology of this particular BC subtype is essential for determining targets for future therapeutic options. No significant financial relationships to disclose.

Download Full-text

Cancer-specific survival by stage of bladder and urinary tract cancers and factors collected by Mallorca Cancer Registry associated to survival.

10.21203/rs.2.22589/v2 ◽

2020 ◽

Author(s):

Maria Ramos ◽

Joana Ripoll ◽

Juan José Montaño ◽

Jaume Pons ◽

Alberto Ameijide ◽

...

Keyword(s):

Urinary Tract ◽

Cancer Registry ◽

Cox Model ◽

Stage Iv ◽

Stage I ◽

Stage Ii ◽

Stage Iii ◽

Cancer Specific Survival ◽

Non Invasive

Abstract Background: Information about survival by stage in bladder cancer is scarce. Objectives: 1) to find out the distribution of bladder and urinary tract cancers by stage; 2) to determine cancer-specific survival by stage of bladder and urinary tract cancers; 3) to identify factors that explain and predict the likelihood of survival and the risk of dying from these cancers.Methods: Incident bladder and urinary tract cancer cases diagnosed between 2006 and 2011 were identified through the Mallorca Cancer Registry. Inclusion criteria: cases with codes C65–C68 (ICD-O 3) with any behaviour. DCO cases were excluded. We collected: sex; age; date and method of diagnosis; histology (ICD-O 3); T, N, M and stage at the time of diagnosis; and date of follow-up or death. End of follow up was 31 December 2015. Multiple imputation (MI) was performed to estimate cases with unknown stage. Actuarial and Kaplan-Meier methods and Cox regression models were used.Results: 2060 cases were identified. 15% were women and 65.2% were 65 years or older. 3.7% had no stage (benign or undetermined behaviour) and 12.5% had unknown stage. After MI, 35.7% were in stage Ta (non-invasive papillary carcinoma), 3.1% in stage Tis (carcinoma in situ), 33.3% in stage I, 11.9 % in Stage II, 4.7% in stage III, and 11.1% in stage IV. Survival was 73% at 5 years. Survival by stage: 98% at stage Ta, 88% at stage Tis, 84% at stage I, 44% at stage II, 33% at stage III, and 7% at stage IV. The Cox model showed that age, histology, and stage were associated with survival.Conclusion: Bladder and urinary tract cancers survival vary greatly with stage. The percentage of non-invasive cancers was high. Stage, age and histology are associated to survival, but sex has no association.

Download Full-text

Evaluation of the Overall 5-Year Survival of Breast Cancer at INO: Data from the 5-Year Prospective Database

Tumori Journal ◽

10.1177/0300891620914153 ◽

2020 ◽

Vol 106 (1_suppl) ◽

pp. 23-23

Author(s):

NA Kaddi ◽

NA Berrada ◽

HA Errihani

Keyword(s):

Breast Cancer ◽

Cancer Survival ◽

Metastatic Cancer ◽

Stage Iv ◽

Breast Cancer Survival ◽

Stage I ◽

Stage Ii ◽

Stage Iii ◽

Rank Test ◽

Her2 Positive

Background: Breast cancer is both the most common and deadliest cancer among women in the world. The objective of this study was to assess breast cancer survival rates. Material and Methods: Prospective study conducted at the National Institute of oncology (INO) Sidi Mohamed Ben Abdellah Rabat .diagnosed patients with cancer from 2013 to 2015. The date of inclusion in the study is the date of histological confirmation of cancer. The survival assessment performed by the Kaplan Meier method, and the comparison between the different classes of a variable was performed by the Log Rank test. Results: 931 cases were collected during this study. According to molecular classification 59% of luminal patients, 25% positive human epidermal growth factor receptors (her2 positive) and 16% basal. The percentage of survival at 5 years, for luminal stage I 93%, stage II 92%, stage III 74% and stage IV 25% ;as well as for basal stage I 92%, stage II 80%, stage III 53% and stage IV 10% ; then the her2 positive stage I 100%, stage II 75% and stage III 70%. Conclusion: The discovery of metastatic cancer decreased breast cancer survival rate, hence the importance of Early Detection Awareness.

Download Full-text

Cause-specific survival by stage of bladder and urinary tract cancers and factors collected by Mallorca Cancer Registry associated to survival

10.21203/rs.2.22589/v1 ◽

2020 ◽

Author(s):

Maria Ramos ◽

Joana Ripoll ◽

Juanjo Montaño ◽

Jaume Pons ◽

Alberto Ameijide ◽

...

Keyword(s):

Urinary Tract ◽

Cancer Registry ◽

Cox Model ◽

Stage Iv ◽

Stage I ◽

Stage Ii ◽

Stage Iii ◽

Non Invasive ◽

Cause Specific Survival

Abstract Background: 1) to find out the distribution of bladder and urinary tract cancers by stage; 2) to determine cause-specific survival by stage of bladder and urinary tract cancers; 3) to identify factors that explain and predict the likelihood of survival and the risk of dying from these cancers.Methods: Incident bladder and urinary tract cancer cases diagnosed between 2006 and 2011 were identified through the Mallorca Cancer Registry. Inclusion criteria: cases with codes C65–C68 according to the ICD-O 3rd edition with any behaviour. Cases identified exclusively through the death certificate were excluded. We collected the following data: sex; age; date and method of diagnosis; histology according to the ICD-O 3rd edition; T, N, M and stage at the time of diagnosis; and date of follow-up or death. End point of follow-up was 31 December 2015. Multiple imputation (MI) was performed to estimate cases with unknown stage. Cases with benign or indeterminate behaviour were excluded for the survival analysis. Actuarial and Kaplan-Meier methods and Cox regression models were used for survival analysis.Results: 2060 cases were identified. 15% were women and 65.2% were 65 years or older. 93.6% consisted of bladder and other urinary tracts. 55.7% were papillary transitional neoplasia, 37.7% solid transitional, 0.6% microcytic, and the rest of other histology. 3.7% had no stage (benign or undetermined behaviour) and 12.5% had unknown stage. After MI, 35.7% were in stage 0a (non-invasive papillary carcinoma), 3.1% in stage 0is (carcinoma in situ), 33.3% in stage I, 11.9 % in Stage II, 4.7% in stage III, and 11.1% in stage IV. Survival was 73% at 5 years. Survival by stage: 98% at stage 0a, 88% at stage 0is, 84% at stage I, 44% at stage II, 33% at stage III, and 7% at stage IV. The Cox model showed that age, histology, and stage were associated with survival.Conclusion: Bladder and urinary tract cancers survival vary greatly with stage, among both non-invasive and invasive cases.

Download Full-text

Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival

BMC Cancer ◽

10.1186/s12885-021-08418-y ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

J. Ripoll ◽

M. Ramos ◽

J. Montaño ◽

J. Pons ◽

A. Ameijide ◽

...

Keyword(s):

Bladder Cancer ◽

Survival Analysis ◽

Cancer Registry ◽

Stage Iv ◽

Stage I ◽

Stage Ii ◽

Stage Iii ◽

Cancer Specific Survival ◽

Non Invasive

Abstract Background Information about survival by stage in bladder cancer is scarce, as well as about survival of non-invasive bladder cancer. The aims of this study are: 1) to find out the distribution of bladder cancer by stage; 2) to determine cancer-specific survival by stage of bladder cancer; 3) to identify factors that explain and predict the likelihood of survival and the risk of dying from these cancers. Methods Incident bladder cancer cases diagnosed between 2006 and 2011 were identified through the Mallorca Cancer Registry. Inclusion criteria: cases with code C67 according to the ICD-O 3rd edition with any behaviour and any histology, except lymphomas and small cell carcinomas. Cases identified exclusively through the death certificate were excluded. We collected the following data: sex; age; date and method of diagnosis; histology according to the ICD-O 3rd edition; T, N, M and stage at the time of diagnosis; and date of follow-up or death. End point of follow-up was 31 December 2015. Multiple imputation (MI) was performed to estimate cases with unknown stage. Cases with benign or indeterminate behaviour were excluded for the survival analysis. Actuarial and Kaplan-Meier methods and Cox regression models were used for survival analysis. Results One thousand nine hundred fourteen cases were identified. 14% were women and 65.4% were 65 years or older. 3.9% had no stage (benign or undetermined behaviour) and 11.5% had unknown stage. After MI, 37.5% were in stage Ta (non-invasive papillary carcinoma), 3.2% in stage Tis (carcinoma in situ), 34.3% in stage I, 11.7% in Stage II, 4.3% in stage III, and 9.0% in stage IV. Survival was 76% at 5 years. Survival by stage: 98% at stage Ta, 90% at stage Tis, 85% at stage I, 45% at stage II, 35% at stage III, and 7% at stage IV. The Cox model showed that age, histology, and stage, but not sex, were associated with survival. Conclusion Bladder cancer survival vary greatly with stage, among both non-invasive and invasive cases. The percentage of non-invasive cancers is high. Stage, age, and histology are associated to survival.

Download Full-text

Breast cancer experience in Uruguay: A 21-year follow up of 1,906 patients in the same institution

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.21163 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 21163-21163

Author(s):

G. D. Krygier ◽

E. Barrios ◽

S. Cataldi ◽

A. Vazquez ◽

R. Alonso ◽

...

Keyword(s):

Breast Cancer ◽

Multivariate Analysis ◽

Prognostic Factors ◽

Latin American ◽

Stage Iv ◽

Stage I ◽

Stage Ii ◽

Node Negative ◽

Incidence And Mortality

21163 Background: Breast cancer is the most common tumor arising in Uruguaian women accounting for 1,930 patients/year (adjusted incidence ratio 83.1/100,000) with 637 death/year (adjusted mortality ratio 24.1/100,000). Both incidence and mortality rank Uruguay at the top of the latinamerican countries ( IARC-GloboCan 2002). We are presenting our final results with 1,906 patients followed during a 21 year period in the biggest private Institution in our country (CENDIMA) and probably amongst all other latin-american countries. Methods: Although this study was initially designed to find a relationship between prognostic factors and survival parameters: OS (overall survival) and DFS (disease free survival) it also describes the epidemiological features of a big breast cancer population in the top ranked country for breast cancer incidence and mortality in Latin America. Statistical analysis was calculated with SPSS (11.0 version) and SAS (6.0 version) programs. OS and DFS results were obtained through Kaplan Meier method. Log rank test was implemented for univariate analysis and Cox proportional hazard rates were used for multivariate analysis. Results: The median age at diagnosis was 61.0 (SD 13.5). Ductal infiltrating carcinoma (DIC) accounted for more than 80% of patients and 56% were node negative (N0) patients at diagnosis. Stratification was: Stage 0: 8.6%, Stage I: 31.5%, Stage II: 41.8%, Stage III: 16.6%, Stage IV: 1.5%. For OS, the axillary status and hystologic grade showed the highest relative ratio (RR) value: 2.49 and 2.40. The nodal status was the main prognostic factor related to DFS with a 2.2 RR. The five and ten year survival rate was: 0.96 and 0.92 (stage I), 0.84 and 0.71 (stage II), 0.71 and 0.56 (stage III) and 0.39 and 0.29 (stage IV) respectively. Conclusions: This is the final analysis of our population in Uruguay representing the biggest report in breast pathology in a latin-american country with a long follow up period (more than 20 years). Our “good” survival results may reflect the initially low risk population at diagnosis (56% node negative, 40.1% stage 0-I ). Nodal status, histologic grade and staging at diagnosis were independent prognostic factors in univariate and multivariate analysis. No significant financial relationships to disclose.

Download Full-text

Postmastectomy radiotherapy in male breast cancer –20 Years follow-up data

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0031-1286451 ◽

2011 ◽

Vol 71 (08) ◽

Author(s):

H Eggemann ◽

A Ignatov ◽

R Stabenow ◽

G von Minkwitz ◽

FW Röhl ◽

...

Keyword(s):

Breast Cancer ◽

Male Breast Cancer ◽

Male Breast ◽

Postmastectomy Radiotherapy

Download Full-text

Identification of biomarkers and functional modules from genomic data in stage-wise breast cancer

Current Bioinformatics ◽

10.2174/1574893615999200922123104 ◽

2020 ◽

Vol 15 ◽

Author(s):

Athira K ◽

Vrinda C ◽

Sunil Kumar P V ◽

Gopakumar G

Keyword(s):

Breast Cancer ◽

Expression Patterns ◽

Differential Expression Analysis ◽

Predictive Biomarkers ◽

Stage I ◽

Stage Ii ◽

Stage Iii ◽

Functional Modules ◽

Incidence And Mortality ◽

Multiple Stages

Background: Breast cancer is the most common cancer in women across the world, with high incidence and mortality rates. Being a heterogeneous disease, gene expression profiling based analysis plays a significant role in understanding breast cancer. Since expression patterns of patients belonging to the same stage of breast cancer vary considerably, an integrated stage-wise analysis involving multiple samples is expected to give more comprehensive results and understanding of breast cancer. Objective: The objective of this study is to detect functionally significant modules from gene co-expression network of cancerous tissues and to extract prognostic genes related to multiple stages of breast cancer. Methods: To achieve this, a multiplex framework is modelled to map the multiple stages of breast cancer, which is followed by a modularity optimization method to identify functional modules from it. These functional modules are found to enrich many Gene Ontology terms significantly that are associated with cancer. Result and Discussion: predictive biomarkers are identified based on differential expression analysis of multiple stages of breast cancer. Conclusion: Our analysis identified 13 stage-I specific genes, 12 stage-II specific genes, and 42 stage-III specific genes that are significantly regulated and could be promising targets of breast cancer therapy. That apart, we could identify 29, 18 and 26 lncRNAs specific to stage I, stage II and stage III respectively.

Download Full-text